Search Results
Your search for can matches 13758 pages
Showing 4651 - 4700Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
ASTRO Issues Clinical Guideline on Radiation Therapy for Cervical Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline—ASTRO's first for cervical cancer—outlines indications and best practices for external-beam radiation...
Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract...
Positive Findings in NSCLC for First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy
It is becoming more challenging to select first-line therapy for advanced non–small cell lung cancer (NSCLC) for patients whose tumors have no EGFR or ALK alterations. The results of two different studies presented at the ASCO20 Virtual Scientific Program—CheckMate 227 and CheckMate 9LA—support the ...
SIR 2020 Virtual: Holographic Visualization for Ablation of Liver Tumors
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of...
Percutaneous Cryoablation vs Partial or Radical Nephrectomy for Early-Stage Kidney Cancer
A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by...
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or...
EHA25 Virtual: Roundup of Findings in Leukemia, Lymphoma, and More
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
FDA Approves Nine-Valent HPV Vaccine for the Prevention of Certain HPV-Related Head and Neck Cancers
On June 12, Merck announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for Gardasil 9—a human papillomavirus (HPV) nine-valent vaccine—for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58....
Study Finds No Survival Benefit From Local Therapy for de Novo Metastatic Breast Cancer
Women presenting with newly diagnosed de novo metastatic breast cancer derived no additional survival benefit from surgery and radiotherapy given after systemic treatment, although the practice may reduce locoregional progression of disease, according to the results of the phase III E2108 study...
FDA Approves Pegfilgrastim Biosimilar, Pegfilgrastim-apgf
On June 11, the U.S. Food and Drug Administration (FDA) approved a biosimilar to pegfilgrastim (Neulasta), pegfilgrastim-apgf (Nyvepria), to decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a...
National Cost of Cancer Care in the United States Expected to Rise to $246 Billion by 2030
According to research from the National Cancer Institute published by Mariotto et al in Cancer Epidemiology, Biomarkers, and Prevention, the national cancer-attributable cost for medical services and prescription drugs is expected to increase from $183 billion in 2015 to $246 billion by 2030—an...
New Recommendations Outline Approaches to Reduce Burnout in Oncology
An article recently published in JCO Oncology Practice (JCO OP) written by the ASCO Ethics Committee focused on the causes of burnout in oncology, as well as intervention methods. The article provides recommendations for individuals, organizations, and the Society to address burnout and ensure...
The Power of mCODE
ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity. Listen to the full podcast on...
Breastfeeding: A Public Health Strategy for Reducing Risk of Ovarian Cancer
Although early-stage disease is highly curable, most ovarian cancers are diagnosed at later stages due to a lack of effective screening. As a result, less than 50% of women survive beyond 5 years. Improving prevention by identifying modifiable risk factors could dramatically change the outcome of...
Veliparib Plus Chemotherapy Shows Antitumor Activity in Front-Line Treatment of Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
KEYNOTE-555 Supports 6-Week Pembrolizumab Dosing Schedule in Melanoma
A less-frequent, more-convenient dosing schedule for pembrolizumab (400 mg every 6 weeks) was deemed safe and effective in patients with unresectable or metastatic melanoma, according to interim data from cohort B enrolled in the KEYNOTE-555 trial. These findings were presented at the 2020 Virtual...
ACS Survey Finds COVID-19 Health Impact Increasing on Patients With Cancer
An American Cancer Society Cancer Action Network (ACS CAN) survey of patients with cancer and survivors, conducted in May 2020, focused on COVID-19 effects. Compared with a survey conducted in April 2020, 87% of respondents said the pandemic had affected their health care, up from 51% in the...
Expert Point of View: David G. Huntsman, MD
Study discussant David G. Huntsman, MD, Founder and Chief Medical Officer of Contextual Genomics, noted the positive predictive value of DETECT-A was 19%, which increased to 41% with the addition of positron-emission tomography/computed tomography. He pointed out that most cancers detected by the...
Study Shows Blood Test Can Identify Multiple Cancers in Asymptomatic Women
A large, “first-of-its-kind” trial showed that a blood test could identify cancers in women with no history of cancer and who were asymptomatic. Of about 10,000 women enrolled in the study, 134 had positive results on blood screening; 26 of these women were found to have cancers. Conventional...
Expert Point of View: David G. Huntsman, MD
Discussant of the CCGA study, David Huntsman, MD, Founder and Chief Medical Officer of Contextual Genomics, said: “Screening is the peak [for the number of people who could benefit from early detection], but screening is the most challenging. It requires high sensitivity and specificity that is...
Study Finds Blood Test Detects Cancer and Tissue of Origin in Those With or Suspected to Have Cancer
A blood test based on cell-free DNA was able to detect cancer as well as the site of origin in patients with a clinical suspicion of cancer, according to results of the Circulating Cell-Free Genome Atlas (CCGA) study presented at the 2020 American Association for Cancer Research (AACR) Virtual...
Sarcoma Foundation of America Announces 2020 Research Grants
The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, announced it has awarded $750,000 in research funds to scientists as part of its 2020 SFA Research Grant program. Fifteen grants, each worth $50,000, have been awarded to researchers ...
Expert Point of View: Yvonne Chen, PhD, and Joseph Alvarnas, MD
Formal discussant Yvonne Chen, PhD, Associate Professor of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles, said the issue of toxicity was important, since high levels of toxicity were observed in this small group of five patients. “All five patients...
Off-the-Shelf CAR T-Cell Therapy Makes Inroads in Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy known as TruUCAR GC027 may prove to be useful in the treatment of adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and potentially other hematologic malignancies. Preliminary results in a small number of patients...
New Cancer Cachexia Guideline Addresses Common Quality-of-Life Issue
ASCO recently released a new evidence-based guideline regarding the clinical management of cancer cachexia in adults with advanced cancer.1 The guideline is the result of a literature review that included 20 systematic reviews and 13 randomized clinical trials. An expert panel was convened to...
Expert Point of View: TROPHIMMUN Trial
Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...
Cognitive Impairment in Women Treated for Early Breast Cancer: Chemoendocrine Adjuvant Therapy vs Endocrine Therapy Alone
Women with early-stage breast cancer who received adjuvant chemoendocrine therapy reported greater cognitive impairment at 3 and 6 months than women receiving adjuvant endocrine therapy alone, according to the results from a subgroup of women participating in the TAILORx trial.1 By 12 months, the...
The Gambler
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Rates of Testicular Cancer Rising Among Racial/Ethnic Minorities in the United States
Between 2001 and 2016 in the United States, Asian/Pacific Islander men experienced the greatest increase in the incidence of testicular germ cell tumors, followed by Hispanic and American Indian/Alaska Native men, according to a study published by Ghazarian et al in Cancer Epidemiology, Biomarkers...
Phyllis F. Cantor Center for Research in Nursing and Patient Care Services Awarded $1.3 Million for Cancer Projects
Nurse-scientists from the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, Boston, received more than $1.3 million in funding for two separate research projects. The American Association for Cancer Research announced that in partnership...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer
The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...
PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit
In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...
Addition of CD38-Directed Antibody Isatuximab to Multiple Myeloma Armamentarium
The treatment approaches to multiple myeloma have significantly changed over the past decade with the introduction of many new active agents. Among them, the monoclonal antibodies have been one of the most exciting advances in myeloma, complementing their success in other hematologic cancers. In...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer, the ASCO Foundation®. Since its inception 7 years ago, the program has raised nearly $5 million, funded 27 Young Investigator ...
Men of Color Remain Underrepresented in Prostate Cancer Clinical Trials
An analysis of 59 prostate cancer clinical trials based in North America and Europe found that the vast majority of enrollees were non-Hispanic white men, according to a study published by Rencsok et al in Cancer Epidemiology, Biomarkers & Prevention. The proportion of white participants in...
Study Explores Adding Trastuzumab to Radiotherapy for Women With HER2-Positive DCIS
The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction ...
Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Metastatic Esophagogastric Cancer
In a single-center phase II trial reported in The Lancet Oncology, Janjigian et al found that the addition of pembrolizumab to trastuzumab and chemotherapy showed activity in the first-line treatment of HER2-positive metastatic esophagogastric cancer. Study Details The investigator-initiated trial...
RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109). “This trial shows...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial any PSMA-targeted therapy, and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
International Medical and Radiation Oncologist Balances Cancer Research and Clinical Practice
The Revolutions of 1989 that resulted in the end of communist rule in Central and Eastern Europe and beyond began in Poland. Perhaps if not for that social upheaval, the career of internationally renowned oncologist Jacek Jassem, MD, PhD, would have taken a very different path. Dr. Jassem had fled...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
From the United States to Germany and Back Again to Become ASCO President in 2021–2022
ASCO President-Elect Everett E. Vokes, MD, FASCO, is the John E. Ultmann Professor, Chair of the Department of Medicine, and Physician-in-Chief of University of Chicago Medicine and Biological Sciences. After a journey from the United States to Germany and back again, Dr. Vokes arrived at the...
Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at ...
